TD Cowen Starts Sol Gel Technologies Ltd. (SLGL) at Buy

TD Cowen analyst Stacy Ku initiates coverage on Sol Gel Technologies Ltd. (NASDAQ: SLGL) with a Buy rating.

The analyst comments "We are initiating coverage of SLGL with a Buy rating. SGT-610 (topical hedgehog inhibitor/HHI patidegib 2%) is in a refined/optimized Phase III for treatment of BCCs in Gorlin syndrome, with data in Q4. KOLs highlight the large unmet need for alternatives to Moh surgeries, given patient fatigue. '610 is derisked by oral HHIs, with improved tolerability and low efficacy hurdle for a $550MM+ oppy."

For an analyst ratings summary and ratings history on Sol Gel Technologies Ltd. click here. For more ratings news on Sol Gel Technologies Ltd. click here.

Shares of Sol Gel Technologies Ltd. closed at $75.28 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'